ADARx Pharmaceuticals, Inc. · NASDAQ:ADRX
ADARx Pharmaceuticals — Corporate Update (November 2026)
33 slides from ADARx Pharmaceuticals's corporate update, Nov 12, 2026
Slide 1: Focused on Developing Next-Generation siRNA Therapeutics
Focused on Developing Next-Generation siRNA Therapeutics Designed to Treat Broad Spectrum of Diseases November 2026
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this presentation, other than statements of historical facts, are forward-looking statements, including statements regarding our e
Slide 3: Developing next-generation siRNA therapeutics for a broad spectrum of diseases
Developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases ADARx Pharmaceuticals ADVANCING THE POTENTIAL OF siRNA Hepatic: designed to increase depth and durability of clinical response Extrahepatic: ability to selectively target 6 tissue types outside the liver EXP
Slide 4: Management team with deep experience in RNAi medicine
Management team with deep experience in RNAi medicine Shared Vision of Building Next-Generation siRNA Therapeutics Company Rui Zhu, PhD Chief Technology Officer Christopher Claeboe, PhD, MBA Senior Vice President of Operations Zhen Li, PhD President and Chief Executive Officer Jiang Bian, JD Vice Pr
Slide 5: ADARx Pipeline of Next-Generation siRNA Programs
ADARx Pipeline of Next-Generation siRNA Programs 1) A novel, undisclosed target in adipose tissue, which we refer to as “OBE1”, whose reduction in expression has been shown to reduce adiposity, with the objective to reduce body weight and fat while preserving lean mass. For additional details, see
Slide 6: ADARx Differentiation: Technology and Strategy
ADARx Differentiation: Technology and Strategy Core proprietary technologies developed to optimize our siRNA sequences and delivery to both hepatic & extrahepatic tissues MST™ designed with the goal of consistently achieving highest possible inherent potency and durability of siRNA sequences Powered
Slide 7: Reproducibility Demonstrated Across Multiple Clinical Programs
7 CLINICAL DATA Reproducibility Demonstrated Across Multiple Clinical Programs Observed quality, reproducibility and speed potentially enable scalable & efficient pipeline expansion Onvuzosiran PKK Agazisiran CFB Quality Clinical Data Observed Precise, deep and durable activity Generally well-tolera
Slide 8: Unlocking Extrahepatic Tissue Access for siRNA
ADARx strategic focus developed to overcome siRNA limitations: Unlocking Extrahepatic Tissue Access for siRNA May Drive Future Pipeline Expansion ADARx technology has Shown the ability to selectively target six extrahepatic tissues Neuron Adipose Eye Skeletal Muscle Microglia Cardiac Muscle Extrahep
Slide 9: Agazisiran
Agazisiran A potent long-acting siRNA silencing complement factor B (CFB) mRNA in development for the treatment of multiple complement-mediated diseases
Slide 10: Agazisiran Has Pipeline-in-a-Product Potential with Three Ph2 Trials Ongoing
Agazisiran Has Pipeline-in-a-Product Potential with Three Ph2 Trials Ongoing We believe FDA’s approval of the complement factor B (CFB) inhibitor FABHALTA® validates CFB as a target in the complement pathway, which is implicated in the pathophysiology of a broad range of complement-mediated diseases
Slide 11: Near-complete inhibition of AP after a single SC injection of agazisiran
At 6.0 mg/kg, we observed near-complete inhibition of AP after a single SC injection of agazisiran A mean inhibition of 99.9% of the complement AP activity was achieved at nadir Suppression sustained for at least 6 months with a mean reduction of 98.3% and 93.5% through 6mo in AP & CFB No observed i
Slide 12: Agazisiran Phase 2 Trial Designs and Endpoints
Program Trial Design Protocol Summary Endpoints Renal Diseases (IgAN, C3G, IC-MPGN) Global, multi-center, open-label multiple dose Phase 2 POC (N = Up to 85) Evaluates SC agazisiran across IgAN, C3G and IC-MPGN Five cohorts* Primary: safety and tolerability Key Secondary: change from baseline in UPC
Slide 13: Onvuzosiran
Onvuzosiran A potent long-acting siRNA silencing PKK mRNA in development for the prevention of HAE attacks
Slide 14: Onvuzosiran targets PKK mRNA for prevention of HAE attacks
s Onvuzosiran is designed to selectively target and degrade PKK mRNA in the liver and prevent protein synthesis, thereby reducing PKK protein levels and preventing activation of bradykinin In Phase 1 at 6 mg/kg, we observed that a single SC injection reduced circulating PKK/KK levels by a mean of 94
Slide 15: Onvuzosiran Observed Deep and Durable Target Knockdown
At the 6 mg/kg dose level, we observed that a single SC injection reduced circulating PKK/KK levels by a mean of 94% at nadir and maintained 84% mean suppression at 6 months Three of the four participants reached below LLOQ* for PKK/KK levels at nadir Well-tolerated with doses up to 6.0 mg/kg, no tr
Slide 16: STOP-HAE Phase 3 Study of Onvuzosiran
16 STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Onvuzosiran Targeting Prekallikrein in Subjects With Hereditary Angioedema Phase 3 global study ongoing 300 mg Q6M Cohort: Phase 1 support: 94% mean (88-97%) reduction at nadir, 84% mean (78-92%) reduction at 6mo at 300 mg
Slide 17: Onvuzosiran: Interim Phase 2a Results
Onvuzosiran: Interim Phase 2a Results * Per feedback from FDA, for onvuzosiran Phase 3 study, HAE attacks before Day 22 will be excluded from primary endpoint analysis, consistent with the siRNA proposed mechanism of action. Interim data as of the November 5, 2026 cutoff date Phase 2a: Dosed at Q6M,
Slide 18: ADX-626
ADX-626 A potent long-acting siRNA silencing coagulation Factor XI (FXI) in development for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation
Slide 19: ADX-626 Addresses Large Unmet Need in Stroke Prevention
Large unmet need In an ongoing Phase 1 study, after single SC dose of ADX-626, observed a mean reduction of 97.4% and 95.4% at nadir in FXI protein and FXI activity, respectively1; will not evaluate higher doses in Phase 1; intend to evaluate higher doses in the planned Phase 2 trial Well-tolerated
Slide 20: ADX-626 NHP Data: Deep and Sustained FXI Protein Suppression
ADX-626 NHP Data: Observed that a Single SC Injection Demonstrated Deep and Sustained FXI Protein Suppression in NHP Study 20 Single SC dose achieved near-complete, sustained reduction of FXI protein in NHP (up to 99.6% reduction of FXI protein at Day 29 and maintained >95% reduction of FXI protein
Slide 21: ADX-626: Deep and Durable Target Reduction in Ongoing Phase 1
ADX-626: Deep and Durable Target Reduction Observed in Ongoing Phase 1 Study1 Deep target reduction: We observed that a single SC dose at 400 mg dose reduced the mean of 97.4% and 95.4% at nadir in FXI protein and FXI activity, respectively (Four of the six participants were below LLOQ for FXI activ
Slide 22: ADX-077
ADX-077 siRNA preclinical therapeutic candidate for obesity via a novel undisclosed target in adipose tissue
Slide 23: ADX-077 Selectively Inhibits Novel Target in Adipose Tissue
ADX-077 Designed to Selectively Inhibit a Novel Target in Adipose Tissue with Encouraging Weight Loss Data in Obese NHPs ADX-077 was designed to selectively inhibit an undisclosed target (“OBE1”) in adipose tissue OBE1 reduces adiposity through mechanism distinct from appetite suppression associated
Slide 24: Deep, Durable Fat Loss With Lean Muscle Preserved in DIO Mice
Observed Deep, Durable Fat Loss With Lean Muscle Preserved in DIO Mice Observed deep target mRNA reduction Durable weight loss observed Meaningful and durable reduction observed in both visceral and subcutaneous fat with no lean mass loss Well-tolerated with repeat-dosing Similar robust results in d
Slide 25: Weight and Fat Reduction Observed in Spontaneous Obese NHPs
Meaningful Effect on Body Weight and Fat Reduction Observed in Spontaneous Obese NHPs ADX-077: Encouraging NHP Data ADX-077 Steady weight loss and meaningful fat mass reduction observed in obese NHPs Preserved lean mass Cross-study results suggest potentially comparable fat-mass reduction to publish
Slide 26: ADX-199
ADX-199 siRNA preclinical therapeutic candidate for selectively silencing and degrading APP mRNA in neurons for neurodegenerative diseases
Slide 27: ADX-199 Selectively Silences APP mRNA Across Brain Regions in NHPs
ADX-199 is Designed to Selectively Silence and Degrade APP mRNA with Potent and Durable Reduction Observed Across Various Brain Regions in NHPs ADX-199 is an siRNA therapeutic candidate engineered to selectively reduce APP mRNA in neurons Human genetic evidence indicates that elevated levels of APP
Slide 28: Deep and Durable Target Suppression in NHPs
Targeting a well validated neurodegenerative disease driver (APP) Achieved potent and durable reduction of target APP protein and its downstream neurotoxic A42 peptide with a single dose Generally well-tolerated following a single 60mg IT dose Observed Deep and Durable Target Suppression in NHPs AD
Slide 29: Preferential APP mRNA Knockdown Observed in NHP
Preferential APP mRNA Knockdown Observed in NHP We observed deep APP mRNA reduction across various brain regions at 3 months, including 94.9% knockdown activity in the frontal cortex, a key brain region implicated in Alzheimer’s disease 29 ADX-199 NHP study: IT lumbar Puncture, Single 60 mg dose, 3
Slide 30: ADARx Summary
ADARx Summary
Slide 31: Internally Generated, Wholly Owned Programs for Hepatic and Extrahepatic Tissues
Internally Generated, Wholly Owned Programs Designed to Efficiently Deliver siRNA to Both Hepatic & Extrahepatic Tissues 31 1) As of the June 8, 2026 safety cutoff date; 2) As of the November 5, 2026 cutoff date; 3) As of the August 5, 2026 safety cutoff date; 4) Based on data received as of October
Slide 32: Meaningful Cadence of Data Milestones Anticipated Across Our Portfolio
In addition, certain near-term development milestones across AbbVie collaboration programs Cash, cash equivalents and short-term investments of $901 million as of September 30, 20262 Meaningful Cadence of Data Milestones Anticipated Across Our Portfolio Program 2027 2028 Agazisiran CFB Mid-27: IgAN
Slide 33: Thank you!
Thank you! Innovative. Efficient. Focused.
ADARx Pharmaceuticals — Corporate Update (November 2026) on 6ix